Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

In the Phase III OptiTROP-Lung04 final analysis, sac-TMT extended median overall survival to 25.9 months versus 17.4 months with platinum-based doublet chemotherapy, an 8.5-month gain and 31% lower risk of death (HR 0.69; 95% CI 0.54–0.89; one-sided P=0.0021), after median follow-up of 32.3 months. The prespecified analysis adjusting for subsequent ADC therapy showed median OS of 25.9 versus 16.6 months and a 43% lower risk of death (HR 0.57). No new safety signals were identified; the article reports one Grade 1–2 interstitial lung disease/pneumonitis case in the sac-TMT group (0.5%) and two in the chemotherapy group (1.1%).

Analysis

This is stronger asset validation than a near-term earnings catalyst for Merck (MRK). The key market mechanism is a higher probability that sac-TMT can displace chemotherapy in a defined post-EGFR-TKI setting; if confirmed across geographies, that supports a broader ADC franchise and could pressure incumbent regimens. But a China trial does not establish global efficacy, regulatory acceptance, or commercial uptake, and it is not a head-to-head comparison with competing ADCs. Do not extrapolate this result to the whole TROP2 class.

For MRK, value attribution is especially uncertain: the article describes ex-Greater-China rights and MSD-led global trials, but provides no royalty, milestone, cost-sharing, or revenue terms. Thus the clinical signal may have option value without being material to near-term MRK estimates. Kelun-Biotech is the more direct asset exposure, though reimbursement-driven volume and pricing are both relevant to realized economics.

The next 1–3 month catalysts are global trial updates and regulatory developments; the 6–18 month question is whether efficacy, safety, and adoption translate across settings. Risks include weaker results outside China, competition from other ADCs, and pricing/access constraints. The adjusted survival analysis is supportive, not a substitute for the randomized primary comparison. A global efficacy setback, safety signal, or disappointing uptake would invalidate the positive read-through.

Key Decisions for Investors

• MRK: stay neutral; do not trade this announcement as an earnings revision. Reassess only after verifying the licensing economics and whether global trial success could generate material, attributable cash flows.
• Kelun-Biotech: treat as a catalyst/watch item rather than chase the release. Track post-approval uptake, reimbursement-driven net pricing, and upcoming global or China trial readouts before underwriting durable sales.
• Avoid a sector-wide short of competing ADC developers: this study provides no direct comparative evidence. Revisit relative positioning if a head-to-head result or a clear change in standard-of-care adoption emerges.
• Falsification triggers: a materially weaker global efficacy/safety profile, regulatory setbacks, or uptake that fails to convert approvals into revenue; for MRK, evidence that its contractual economics are too small to affect estimates would remove the read-through.